amitriptyline has been researched along with Weight Gain in 17 studies
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.
amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The tricyclic antidepressant amitriptyline (AMT) and the calcium channel blocker flunarizine are frequently used in the preventive treatment of migraine, but the side-effect of prominent weight gain that frequently emerges during preventive treatment of migraine with these agents often leads to the discontinuation of therapy." | 9.11 | Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. ( Berilgen, MS; Bulut, S; Dag, E; Gonen, M; Mungen, B; Tekatas, A, 2005) |
| "This study was designed to determine (1) whether chronic amitriptyline administration was effective in alleviating symptoms of neuropathic pain in a rat model of spinal nerve injury, and (2) whether the effect of amitriptyline involved manipulation of endogenous adenosine, by determining the effect of caffeine, a non-selective adenosine A(1) and A(2) receptor antagonist, on its actions." | 7.71 | Chronic administration of amitriptyline and caffeine in a rat model of neuropathic pain: multiple interactions. ( Allen, GV; Chase, T; Esser, MJ; Sawynok, J, 2001) |
| "The tricyclic antidepressant amitriptyline (AMT) and the calcium channel blocker flunarizine are frequently used in the preventive treatment of migraine, but the side-effect of prominent weight gain that frequently emerges during preventive treatment of migraine with these agents often leads to the discontinuation of therapy." | 5.11 | Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. ( Berilgen, MS; Bulut, S; Dag, E; Gonen, M; Mungen, B; Tekatas, A, 2005) |
| "Compared with citalopram, in models adjusted for sociodemographic and clinical features, significantly decreased rate of weight gain was observed among individuals treated with bupropion (β [SE]: -0." | 3.80 | An electronic health records study of long-term weight gain following antidepressant use. ( Blumenthal, SR; Castro, VM; Churchill, SE; Clements, CC; Erb, JL; Fava, M; Kohane, IS; Murphy, SN; Perlis, RH; Rosenfield, HR; Smoller, JW; Weilburg, JB, 2014) |
| "This study was designed to determine (1) whether chronic amitriptyline administration was effective in alleviating symptoms of neuropathic pain in a rat model of spinal nerve injury, and (2) whether the effect of amitriptyline involved manipulation of endogenous adenosine, by determining the effect of caffeine, a non-selective adenosine A(1) and A(2) receptor antagonist, on its actions." | 3.71 | Chronic administration of amitriptyline and caffeine in a rat model of neuropathic pain: multiple interactions. ( Allen, GV; Chase, T; Esser, MJ; Sawynok, J, 2001) |
| "Thirty-nine migraine patients with a body mass index <25 kg/m(2) and without endocrinological or metabolic diseases were assigned to two treatment groups, one receiving amitryptiline, the other flunarizine, for 3 months." | 2.76 | Migraine preventive drug-induced weight gain may be mediated by effects on hypothalamic peptides: the results of a pilot study. ( Calabresi, P; Caproni, S; Corbelli, I; Cupini, ML; Pini, LA; Sarchielli, P, 2011) |
| "Migraine, particularly migraine with aura, and increased body weight are independent risk factors for cardiovascular disease (CVD)." | 2.74 | Weight change and clinical markers of cardiovascular disease risk during preventive treatment of migraine. ( Bigal, ME; Biondi, DM; Hulihan, J; Lipton, RB; Xiang, J, 2009) |
| "A total of 73 patients with migraine headache with or without aura are included in this single-center, double-blind, randomized, and controlled trial." | 2.73 | A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. ( Aydinli, I; Keskinbora, K, 2008) |
| "Amitriptyline was dosed as follows: 8 mg/day for 6 days, 8 mg twice a day for 6 days, 20 mg/day for 6 days, and 20 mg twice a day for 45 days." | 2.70 | Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. ( Alves, LA; Barbosa, JS; Krymchantowski, AV; Silva, MT, 2002) |
| "Weight gain was detected only in patients receiving amitryptiline." | 2.66 | Efficacy and tolerability of fluoxetine in the elderly: a double-blind study versus amitryptiline. ( Altamura, AC; Guercetti, G; Invernizzi, G; Percudani, M, 1989) |
| "Mirtazapine is a noradrenergic and specific serotonergic antidepressant, characterized by a unique pharmacologic profile, favorable pharmacokinetics, and proven efficacy and safety." | 2.40 | Mirtazapine: clinical advantages in the treatment of depression. ( Burrows, GD; Kremer, CM, 1997) |
| "No treatments for Farber disease are clinically available, and affected patients have a severely shortened lifespan." | 1.51 | Acid Sphingomyelinase Deficiency Ameliorates Farber Disease. ( Becker, KA; Beckmann, N; Carpinteiro, A; Edwards, MJ; Gulbins, E; Kadow, S; Kleuser, B; Kramer, M; Kühn, C; Schulz-Schaeffer, WJ; Schumacher, F, 2019) |
| " These findings suggest that the chronic administration of amitriptyline or venlafaxine at 5 mg/kg, but not 10 mg/kg, may be neuroprotective to hippocampal neurons." | 1.32 | Dose-related effects of chronic antidepressants on neuroprotective proteins BDNF, Bcl-2 and Cu/Zn-SOD in rat hippocampus. ( Li, XM; Steven Richardson, J; Xu, H, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.76) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 9 (52.94) | 29.6817 |
| 2010's | 4 (23.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beckmann, N | 1 |
| Becker, KA | 1 |
| Kadow, S | 1 |
| Schumacher, F | 1 |
| Kramer, M | 1 |
| Kühn, C | 1 |
| Schulz-Schaeffer, WJ | 1 |
| Edwards, MJ | 1 |
| Kleuser, B | 1 |
| Gulbins, E | 1 |
| Carpinteiro, A | 1 |
| Blumenthal, SR | 1 |
| Castro, VM | 1 |
| Clements, CC | 1 |
| Rosenfield, HR | 1 |
| Murphy, SN | 1 |
| Fava, M | 1 |
| Weilburg, JB | 1 |
| Erb, JL | 1 |
| Churchill, SE | 1 |
| Kohane, IS | 1 |
| Smoller, JW | 1 |
| Perlis, RH | 1 |
| Keskinbora, K | 1 |
| Aydinli, I | 1 |
| Bigal, ME | 1 |
| Lipton, RB | 1 |
| Biondi, DM | 1 |
| Xiang, J | 1 |
| Hulihan, J | 1 |
| Caproni, S | 1 |
| Corbelli, I | 1 |
| Pini, LA | 1 |
| Cupini, ML | 1 |
| Calabresi, P | 1 |
| Sarchielli, P | 1 |
| Schilling, C | 1 |
| Gilles, M | 1 |
| Blum, WF | 1 |
| Daseking, E | 1 |
| Colla, M | 1 |
| Weber-Hamann, B | 1 |
| Lederbogen, F | 1 |
| Krumm, B | 1 |
| Heuser, I | 1 |
| Wudy, SA | 1 |
| Kopf, D | 1 |
| Deuschle, M | 1 |
| Krymchantowski, AV | 1 |
| Silva, MT | 1 |
| Barbosa, JS | 1 |
| Alves, LA | 1 |
| Xu, H | 1 |
| Steven Richardson, J | 1 |
| Li, XM | 1 |
| Meyer, MA | 1 |
| Berilgen, MS | 1 |
| Bulut, S | 1 |
| Gonen, M | 1 |
| Tekatas, A | 1 |
| Dag, E | 1 |
| Mungen, B | 1 |
| Maggioni, F | 1 |
| Ruffatti, S | 1 |
| Dainese, F | 1 |
| Mainardi, F | 1 |
| Zanchin, G | 1 |
| Szarek, BL | 1 |
| Brandt, DM | 1 |
| Burrows, GD | 1 |
| Kremer, CM | 1 |
| Sansone, RA | 1 |
| Wiederman, MW | 1 |
| Shrader, JA | 1 |
| Esser, MJ | 1 |
| Chase, T | 1 |
| Allen, GV | 1 |
| Sawynok, J | 1 |
| Altamura, AC | 1 |
| Percudani, M | 1 |
| Guercetti, G | 1 |
| Invernizzi, G | 1 |
| Fernstrom, MH | 1 |
| Kupfer, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hypothalamus-pituitary-adrenal System: Role of the Mineralocorticoid Receptor and Longitudinal Study in Depressed Patients[NCT01049347] | Phase 3 | 127 participants (Actual) | Interventional | 1997-10-31 | Completed | ||
| Efficacy and Safety Analyses of Mirtazapine in the Treatment of Malignant Tumor Related Depression: A Phase II, Placebo-controlled, Randomized, Double-blinded Clinical Trial in Advanced Non-small Cell Lung Cancer Patients[NCT02650544] | Phase 2 | 236 participants (Anticipated) | Interventional | 2015-12-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for amitriptyline and Weight Gain
| Article | Year |
|---|---|
Mirtazapine: clinical advantages in the treatment of depression.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Clomipramine | 1997 |
9 trials available for amitriptyline and Weight Gain
| Article | Year |
|---|---|
A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine.
Topics: Adult; Amitriptyline; Anticonvulsants; Antidepressive Agents, Tricyclic; Constipation; Disorders of | 2008 |
Weight change and clinical markers of cardiovascular disease risk during preventive treatment of migraine.
Topics: Adult; Amitriptyline; Analgesics, Non-Narcotic; Biomarkers; Blood Pressure; Cardiovascular Diseases; | 2009 |
Migraine preventive drug-induced weight gain may be mediated by effects on hypothalamic peptides: the results of a pilot study.
Topics: Adult; Amitriptyline; Analgesics, Non-Narcotic; Female; Flunarizine; Humans; Hypothalamus; Male; Mid | 2011 |
Leptin plasma concentrations increase during antidepressant treatment with amitriptyline and mirtazapine, but not paroxetine and venlafaxine: leptin resistance mediated by antihistaminergic activity?
Topics: Adult; Aged; Aged, 80 and over; Amitriptyline; Analysis of Variance; Antidepressive Agents; Biomarke | 2013 |
Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Constipation; Double-Blind Method; Drug Therapy, | 2002 |
Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Body Mass Index; C-Peptide; Female; Flunariz | 2005 |
Weight variations in the prophylactic therapy of primary headaches: 6-month follow-up.
Topics: Adrenergic beta-Antagonists; Adult; Amines; Amitriptyline; Analgesics, Non-Narcotic; Anticonvulsants | 2005 |
Efficacy and tolerability of fluoxetine in the elderly: a double-blind study versus amitryptiline.
Topics: Aged; Amitriptyline; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Ran | 1989 |
Antidepressant-induced weight gain: a comparison study of four medications.
Topics: Adult; Amitriptyline; Antidepressive Agents; Depressive Disorder; Desipramine; Female; Humans; Male; | 1988 |
7 other studies available for amitriptyline and Weight Gain
| Article | Year |
|---|---|
Acid Sphingomyelinase Deficiency Ameliorates Farber Disease.
Topics: Acid Ceramidase; Amitriptyline; Animals; Ceramides; Cytokines; Farber Lipogranulomatosis; Mice, Inbr | 2019 |
An electronic health records study of long-term weight gain following antidepressant use.
Topics: Adult; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bo | 2014 |
Dose-related effects of chronic antidepressants on neuroprotective proteins BDNF, Bcl-2 and Cu/Zn-SOD in rat hippocampus.
Topics: Amitriptyline; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Brain-Derived Neuro | 2003 |
Persistent low back pain.
Topics: Amitriptyline; Analgesics, Non-Narcotic; Chronic Disease; Humans; Low Back Pain; Muscle Relaxants, C | 2005 |
A comparison of weight changes with fluoxetine, desipramine, and amitriptyline: a retrospective study of psychiatric inpatients.
Topics: Amitriptyline; Body Weight; Desipramine; Dose-Response Relationship, Drug; Drug Therapy, Combination | 1993 |
Naturalistic study of the weight effects of amitriptyline, fluoxetine, and sertraline in an outpatient medical setting.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Amitriptyline; Antidepressive Agents, Second-Genera | 2000 |
Chronic administration of amitriptyline and caffeine in a rat model of neuropathic pain: multiple interactions.
Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Caffeine; Disease Models | 2001 |